Literature DB >> 20881229

Pharmacometrics 2020.

Jogarao V S Gobburu1.   

Abstract

This special issue of the Journal of Clinical Pharmacology is dedicated to pharmacometrics, covering topics related to methodological research, application to decisions, standardization, PhRMA survey, and growth strategy. Innovative methodological and technological advances in analyzing disease, drug, and trial data have equipped pharmacometricians with the know-how to influence high-level decisions, which in turn creates more pharmacometric opportunities. Pharmacometrics is revolutionizing drug development and regulatory decision making. To sustain the success and growth of this field, we need to up the ante. Strategic goals for pharmacometric groups in industry, regulatory agencies, and academia are proposed in this report. These goals should be of significance to all stakeholders who have a vested interest in drug development and therapeutics. The future of pharmacometrics depends on how well we all can deliver on the strategic goals.

Mesh:

Substances:

Year:  2010        PMID: 20881229     DOI: 10.1177/0091270010376977

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  15 in total

Review 1.  Role of modelling and simulation: a European regulatory perspective.

Authors:  Siv Jönsson; Anja Henningsson; Monica Edholm; Tomas Salmonson
Journal:  Clin Pharmacokinet       Date:  2012-02-01       Impact factor: 6.447

Review 2.  Quantitative clinical pharmacology is transforming drug regulation.

Authors:  Carl C Peck
Journal:  J Pharmacokinet Pharmacodyn       Date:  2010-10-27       Impact factor: 2.745

3.  Model-Based Residual Post-Processing for Residual Model Identification.

Authors:  Moustafa M A Ibrahim; Rikard Nordgren; Maria C Kjellsson; Mats O Karlsson
Journal:  AAPS J       Date:  2018-07-02       Impact factor: 4.009

4.  Magnitude of Increased Infliximab Clearance Imposed by Anti-infliximab Antibodies in Crohn's Disease Is Determined by Their Concentration.

Authors:  Helena Edlund; Casper Steenholdt; Mark A Ainsworth; Eva Goebgen; Jørn Brynskov; Ole Ø Thomsen; Wilhelm Huisinga; Charlotte Kloft
Journal:  AAPS J       Date:  2016-10-13       Impact factor: 4.009

Review 5.  Enhancing population pharmacokinetic modeling efficiency and quality using an integrated workflow.

Authors:  Henning Schmidt; Andrijana Radivojevic
Journal:  J Pharmacokinet Pharmacodyn       Date:  2014-07-24       Impact factor: 2.745

6.  Exposure-response relationship of AMG 386 in combination with weekly paclitaxel in recurrent ovarian cancer and its implication for dose selection.

Authors:  Jian-Feng Lu; Erik Rasmussen; Beth Y Karlan; Ignace B Vergote; Lynn Navale; Mita Kuchimanchi; Rebeca Melara; Daniel E Stepan; David M Weinreich; Yu-Nien Sun
Journal:  Cancer Chemother Pharmacol       Date:  2012-01-01       Impact factor: 3.333

7.  White paper: landscape on technical and conceptual requirements and competence framework in drug/disease modeling and simulation.

Authors:  G Vlasakakis; E Comets; A Keunecke; I Gueorguieva; P Magni; N Terranova; O Della Pasqua; E C de Lange; C Kloft
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2013-05-01

Review 8.  Drug Development for Pediatric Populations: Regulatory Aspects.

Authors:  Jochen Zisowsky; Andreas Krause; Jasper Dingemanse
Journal:  Pharmaceutics       Date:  2010-11-29       Impact factor: 6.321

9.  Use of a linearization approximation facilitating stochastic model building.

Authors:  Elin M Svensson; Mats O Karlsson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2014-03-13       Impact factor: 2.745

10.  Visualization and communication of pharmacometric models with berkeley madonna.

Authors:  A Krause; P J Lowe
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2014-05-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.